

This notice in TED website: <https://ted.europa.eu/udl?uri=TED:NOTICE:468163-2019:TEXT:EN:HTML>

**United Kingdom-Runcorn: Pharmaceutical products
2019/S 193-468163**

Contract notice

Supplies

Legal Basis:

Directive 2014/24/EU

Section I: Contracting authority

I.1) Name and addresses

The NHS Commissioning Board (operating Under the name of NHS England)
2nd Floor, Rutland House
Runcorn
WA7 2ES
United Kingdom
E-mail: michelle.clarke6@nhs.net
NUTS code: UK

Internet address(es):

Main address: <https://nhsengland.bravosolutio.co.uk>

I.2) Information about joint procurement

The contract is awarded by a central purchasing body

I.3) Communication

The procurement documents are available for unrestricted and full direct access, free of charge, at: <https://nhsenland.bravosolution.co.uk>

Additional information can be obtained from the abovementioned address

Tenders or requests to participate must be submitted electronically via: <https://nhsenland.bravosolution.co.uk>

Tenders or requests to participate must be submitted to the abovementioned address

Electronic communication requires the use of tools and devices that are not generally available.

Unrestricted and full direct access to these tools and devices is possible, free of charge, at: <https://nhsenland.bravosolution.co.uk>

I.4) Type of the contracting authority

Ministry or any other national or federal authority, including their regional or local subdivisions

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title:

NHS Framework for the NHS North of England Region, Branded Medicines – Tranche B, Cytokine Modulators and other Monoclonal Antibodies, and Fondaparinux
Reference number: CM/PHR/16/5527

II.1.2) Main CPV code

33600000

II.1.3) **Type of contract**

Supplies

II.1.4) **Short description:**

NHS Framework for the NHS North of England Region, Branded Medicines – Tranche B, Cytokine Modulators and other Monoclonal Antibodies, and Fondaparinux.

Offer reference number: CM/PHR/16/5527

CM/PHR/16/5527/01 — Tranche B: 1.3.2020 to 28.2.2022 with an option to extend (at the authority's discretion) for a period or periods up to a total of 24 months.

CM/PHR/16/5527/02 – Annual tranche — cytokine modulators and other monoclonal antibodies — 1.3.2020 to 28.2.2021 with an option to extend (at the authority's discretion) for a period or periods up to a total of 12 months.

CM/PHR/16/5527/03 – NHS framework agreement for Fondaparinux — London – 1.3.2020 – 31.8.2021, South of England – 1.3.2020 – 31.8.2020, Midlands and East – 1.3.2020 – 28.2.2021, all with an option to extend (at the authority's discretion) for a period or periods up to a total of 24 months.

II.1.5) **Estimated total value**

Value excluding VAT: 987 906 001.00 GBP

II.1.6) **Information about lots**

This contract is divided into lots: yes

Tenders may be submitted for all lots

II.2) **Description**

II.2.1) **Title:**

NHS Framework for the NHS North of England Region, Branded Medicines – Tranche B

Lot No: 1

II.2.2) **Additional CPV code(s)**

33600000

II.2.3) **Place of performance**

NUTS code: UKC

NUTS code: UKD

NUTS code: UKE

Main site or place of performance:

Please refer to document 03 schedule 8 in the ITO documents for the full list of purchasing points.

II.2.4) **Description of the procurement:**

CM/PHR/16/5527/01 — 1.3.2020 to 28.2.2022 – NHS Framework for the NHS North of England Region, Branded Medicines – Tranche B with an option to extend (at the authority's discretion) for a period or periods up to a total of 24 months.

II.2.5) **Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) **Estimated value**

II.2.7) **Duration of the contract, framework agreement or dynamic purchasing system**

Start: 01/03/2020

End: 28/02/2022

This contract is subject to renewal: no

II.2.10) **Information about variants**

Variants will be accepted: yes

II.2.11) **Information about options**

Options: no

II.2.12) **Information about electronic catalogues**

II.2.13) **Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds: no

II.2.14) **Additional information**

II.2) **Description**

II.2.1) **Title:**

NHS Framework for the NHS North of England Region, Branded Medicines – Annual Tranche — Cytokine Modulators and other Monoclonal Antibodies

Lot No: 2

II.2.2) **Additional CPV code(s)**

33600000

II.2.3) **Place of performance**

NUTS code: UKC

NUTS code: UKD

NUTS code: UKE

Main site or place of performance:

Please refer to document 3 schedule 8 in the ITO pack for full list of purchasing points.

II.2.4) **Description of the procurement:**

CM/PHR/16/5527/02 – 1.3.2020 to 28.2.2021 — NHS Framework for the NHS North of England Region, Branded Medicines – Annual Tranche — cytokine modulators and other monoclonal antibodies with an option to extend (at the authority's discretion) for a period or periods up to a total of 12 months.

II.2.5) **Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) **Estimated value**

II.2.7) **Duration of the contract, framework agreement or dynamic purchasing system**

Start: 01/03/2020

End: 28/02/2021

This contract is subject to renewal: no

II.2.10) **Information about variants**

Variants will be accepted: yes

II.2.11) **Information about options**

Options: no

II.2.12) **Information about electronic catalogues**

II.2.13) **Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds: no

II.2.14) **Additional information**

II.2) **Description**

II.2.1) **Title:**

NHS Framework Agreement for Fondaparinux
Lot No: 3

II.2.2) **Additional CPV code(s)**
33600000

II.2.3) **Place of performance**
NUTS code: UKC
NUTS code: UKD
NUTS code: UKE
NUTS code: UKF
NUTS code: UKG
NUTS code: UKH
NUTS code: UKI
NUTS code: UKJ
NUTS code: UKK

Main site or place of performance:

Please refer to document 3 schedule 8 in the ITO documents for a full list of purchasing points.

II.2.4) **Description of the procurement:**
CM/PHR/16/5527/03 – NHS framework agreement for Fondaparinux — London – 1.3.2020 – 31.8.2021, with an option to extend (at the authority's discretion) for a period or periods up to a total of 24 months.
South of England – 1.3.2020 – 31.8.2020, with an option to extend (at the authority's discretion) for a period or periods up to a total of 24 months.
Midlands and East – 1.3.2020 – 28.2.2021, with an option to extend (at the authority's discretion) for a period or periods up to a total of 24 months.

II.2.5) **Award criteria**
Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) **Estimated value**

II.2.7) **Duration of the contract, framework agreement or dynamic purchasing system**
Start: 01/03/2020
End: 21/08/2021
This contract is subject to renewal: no

II.2.10) **Information about variants**
Variants will be accepted: yes

II.2.11) **Information about options**
Options: no

II.2.12) **Information about electronic catalogues**

II.2.13) **Information about European Union funds**
The procurement is related to a project and/or programme financed by European Union funds: no

II.2.14) **Additional information**

Section III: Legal, economic, financial and technical information

III.1) **Conditions for participation**

III.1.1) **Suitability to pursue the professional activity, including requirements relating to enrolment on professional or trade registers**

III.1.2) **Economic and financial standing**

List and brief description of selection criteria:

Please refer to the award criteria contained in the invitation to offer.

III.1.3) Technical and professional ability

List and brief description of selection criteria:

Please refer to the award criteria contained in the invitation to offer.

III.1.5) Information about reserved contracts

III.2) Conditions related to the contract

III.2.2) Contract performance conditions:

III.2.3) Information about staff responsible for the performance of the contract

Section IV: Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.3) Information about a framework agreement or a dynamic purchasing system

The procurement involves the establishment of a framework agreement

Framework agreement with several operators

IV.1.4) Information about reduction of the number of solutions or tenders during negotiation or dialogue

IV.1.6) Information about electronic auction

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: yes

IV.2) Administrative information

IV.2.1) Previous publication concerning this procedure

IV.2.2) Time limit for receipt of tenders or requests to participate

Date: 07/11/2019

Local time: 13:00

IV.2.3) Estimated date of dispatch of invitations to tender or to participate to selected candidates

IV.2.4) Languages in which tenders or requests to participate may be submitted:

English

IV.2.6) Minimum time frame during which the tenderer must maintain the tender

Duration in months: 3 (from the date stated for receipt of tender)

IV.2.7) Conditions for opening of tenders

Date: 07/11/2019

Local time: 13:00

Place:

Runcorn

Information about authorised persons and opening procedure:

Commercial Medicines Unit Employee.

Section VI: Complementary information

VI.1) Information about recurrence

This is a recurrent procurement: no

VI.2) Information about electronic workflows

VI.3) **Additional information:**

Responding to this notice. Any supplier may be disqualified who does not respond to the following in the requisite manner:

1) Submission of expression of interest and procurement specific information. This procurement exercise will be conducted on the eTendering portal at: [www.nhs.uk/bravosolution.co.uk](https://www.nhs.uk/bravosolution)

Candidates wishing to be considered for this procurement exercise must register, and provide additional procurement specific information (if requested), through the eTendering portal as follows:

1.1) If not already registered, candidates should register on the eTendering portal at: [https://www.nhs.uk/bravosolution.co.uk](https://www.nhs.uk/bravosolution) and click the link to register:

- accept the terms and conditions and click continue,
- enter your correct business and user details,
- note the username you chose and click Save when complete,
- you will shortly receive an email with your unique password (please keep this secure).

1.2) Once registered, candidates must express interest as follows:

- (a) login to the eTendering portal;
- (b) select response to ITT;
- (c) select ITTs Open To All Suppliers;
- (d) access listing related to this procurement.

For NHS Framework for the NHS North of England Region, Branded Medicines – Tranche B, Cytokine Modulators and other monoclonal antibodies, and fondaparinux and view details;

(e) click on express interest button at the top of the page;

(f) once you have expressed interest, the ITT will move to My ITTs, where you can download additional documentation (if required), and construct your reply as instructed. You must then publish your reply using the Publish button.

1.3) For any support in registering on the portal or submitting your expression of interest please contact the eTendering Help-desk at +44 800 368 4850 or: help@bravosolution.co.uk

2) General supplier information. To manage and assess supplier information the contracting authority requests candidates provide their company profile in the Governments supplier information database, sid4gov, as follows:

2.1) If not already registered, candidates must go to the following web page: <https://sid4gov.cabinetoffice.gov.uk/> and select Register for sid4gov at the bottom of the page. Key in details as requested to search for your company. If you do not have a D-UNS ® Number, click on the link at the right of the page to obtain a number from D&B. Candidates must obtain a Dun and Bradstreet (D&B) D-U-N-S® Number to enable registration on sid4gov.

2.2) Once registration is complete you are able to create and update your sid4gov company profile. Candidates should ensure all the mandatory fields of their sid4gov profile are completed and up to date for each procurement exercise. D&B data will be supplied automatically by D&B;

2.3) For further help or information concerning sid4gov, please contact the sid4gov Helpdesk at: support@nqc.com or telephone +44 (0) 845 299 2994.

The framework agreement is for the benefit of other participating NHS bodies (whether acting individually, or on behalf of, or together as members of any consortia) along with any other non-NHS bodies which the participants deem necessary for the delivery of services or goods to NHS bodies, local authorities, other government departments or non-departmental public bodies charged with the delivery of healthcare or health related services.

Variants: an offerer is permitted to submit any number of variants to the Authority (subject to the minimum requirements set out in the ITO Terms of Offer Document 2, paragraph 8.2.1.

VI.4) **Procedures for review**

VI.4.1) **Review body**

The Royal Courts of Justice
London or any of the district registry of the High Court
United Kingdom

VI.4.2) **Body responsible for mediation procedures**

VI.4.3) **Review procedure**

VI.4.4) **Service from which information about the review procedure may be obtained**

VI.5) **Date of dispatch of this notice:**

03/10/2019